Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interleukin-33 (IL-33) promotes DNA damage-resistance in lung cancer.

Cell death & disease·2025
Same author

IL-33/ST2 signalling promotes tumor growth by regulating polarization of alternatively activated macrophages.

Cancer biology & medicine·2025
Same author

Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study.

Hepatology international·2022
Same author

Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients.

Journal of gastroenterology and hepatology·2022
Same author

Association between the Phytochemical Index and Overweight/Obesity: A Meta-Analysis.

Nutrients·2022
Same author

Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 study.

Journal of viral hepatitis·2022

Related Experiment Video

Updated: Jun 24, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

IL-33 Inhibits Hepatitis B Virus through Its Receptor ST2 in Hydrodynamic HBV Mouse Model.

Xiuzhu Gao1,2, Xiumei Chi1,2, Xiaomei Wang1

  • 1Department of Hepatology, The First Hospital of Jilin University, Jilin University, 71 XinMin Street, Changchun, Jilin Province 130021, China.

Mediators of Inflammation
|May 16, 2020
PubMed
Summary

Interleukin-33 (IL-33) effectively reduces hepatitis B virus (HBV) DNA and HBsAg in mice by signaling through the ST2 receptor, requiring NK cells for its antiviral action.

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.8K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K

Related Experiment Videos

Last Updated: Jun 24, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.8K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K

Area of Science:

  • Immunology
  • Hepatology
  • Virology

Background:

  • Interleukin-33 (IL-33) is linked to liver damage but its role in hepatitis B virus (HBV) infection is unclear.
  • Investigating IL-33's therapeutic potential in HBV infection is crucial for developing new treatments.

Purpose of the Study:

  • To investigate the role and mechanism of IL-33 in a hydrodynamic HBV mouse model.
  • To determine if IL-33 has direct antiviral effects against HBV infection.

Main Methods:

  • Utilized a hydrodynamic HBV mouse model with varying IL-33 doses.
  • Employed ST2 knockout, NK cell depletion, and immunodeficient mice models.
  • Assessed HBV DNA, HBsAg, HBeAg levels, liver function markers, and intrahepatic HBcAg.

Main Results:

  • IL-33 significantly reduced HBV DNA and HBsAg in a dose-dependent manner in wild-type mice.
  • Antiviral effects were abolished in ST2 knockout mice, indicating receptor dependence.
  • IL-33 required NK cells for antiviral activity in vivo and demonstrated direct anti-HBV effects in vitro.

Conclusions:

  • IL-33 inhibits HBV infection via the ST2 receptor, necessitating NK cell presence.
  • IL-33 exhibits direct antiviral activity against HBV in vitro.
  • IL-33 is a potential therapeutic agent for HBV clearance.